London, United Kingdom, 11th June 2021: Euromedica Executive Search are pleased to announce their successful partnership with Proteomics International Laboratories LTD (ASX: PIQ) to secure Vik Malik as Chief Commercialisation Officer, effective 1st June 2021.
Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) recently announced the expansion of its executive team with the appointments of Vik Malik as its new Chief Commercialisation Officer (CCO).
A worldwide executive search was undertaken in preparation for what is set to be a transformative period for Proteomics International. Medical Technologies commercialisation veteran Vik Malik will lead Proteomics International’s commercial roll-out of the Company's innovative diagnostic products centered on the PromarkerD predictive test for diabetic kidney disease.
Starting 1st June, he will initially be based in the USA. Mr Malik has an extensive network of clinical (KOL) and business professionals in the healthcare, medical device and diagnostics sectors, which will prove invaluable as Proteomics International ramps up the commercialisation of PromarkerD in the US and Europe.
For further information regarding Proteomics International Laboratories LTD and the details of Vik’s appointment, please refer to https://www.proteomics.com.au/newsroom/inthemedia/media-release/
About Proteomics International Laboratories LTD (ASX: PIQ):
Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bioanalytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world’s first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities located on Perth's QEII Medical Campus.
Proteomics International's business model is centred on the commercialisation of the Company's world-leading test for diabetic kidney disease, PromarkerD. The Company offsets the cash burn from R&D and product development through provision of specialist analytical services, whilst using its proprietary PromarkerTM technology platform to create a pipeline of novel diagnostic tests. For more information, visit www.proteomics.com.au